Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to -$4.9 million.

  • Roivant Sciences' Capital Expenditures fell 23027.98% to -$4.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.7 million, marking a year-over-year increase of 5830.14%. This contributed to the annual value of $4.6 million for FY2025, which is 23277.86% up from last year.
  • As of Q4 2025, Roivant Sciences' Capital Expenditures stood at -$4.9 million, which was down 23027.98% from $7.8 million recorded in Q3 2025.
  • In the past 5 years, Roivant Sciences' Capital Expenditures registered a high of $11.2 million during Q4 2021, and its lowest value of -$4.9 million during Q4 2025.
  • Its 5-year average for Capital Expenditures is $3.5 million, with a median of $2.8 million in 2021.
  • Data for Roivant Sciences' Capital Expenditures shows a peak YoY increase of 68795.18% (in 2025) and a maximum YoY decrease of 23027.98% (in 2025) over the last 5 years.
  • Over the past 5 years, Roivant Sciences' Capital Expenditures (Quarter) stood at $11.2 million in 2021, then decreased by 0.94% to $11.1 million in 2022, then tumbled by 90.67% to $1.0 million in 2023, then skyrocketed by 266.7% to $3.8 million in 2024, then plummeted by 230.28% to -$4.9 million in 2025.
  • Its last three reported values are -$4.9 million in Q4 2025, $7.8 million for Q3 2025, and $4.0 million during Q2 2025.